International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 519-523 , June 2010

Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns

  • Audrey Tupin

      Affiliations

    • Université Montpellier 1, Centre d’études d’agents Pathogènes et Biotechnologies pour la Santé (CPBS), CNRS, UMR 5236, 4 Bd Henri IV, CS 69033, F-34965 Montpellier, Cedex 2, France
    • Université Montpellier 2, CPBS, F-34095 Montpellier, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 4 67 54 86 07; fax: +33 4 67 54 86 04.
    • ,
  • Maxime Gualtieri

      Affiliations

    • Université Montpellier 1, Centre d’études d’agents Pathogènes et Biotechnologies pour la Santé (CPBS), CNRS, UMR 5236, 4 Bd Henri IV, CS 69033, F-34965 Montpellier, Cedex 2, France
    • Université Montpellier 2, CPBS, F-34095 Montpellier, France
    • ,
  • Françoise Roquet-Banères

      Affiliations

    • Université Montpellier 1, Centre d’études d’agents Pathogènes et Biotechnologies pour la Santé (CPBS), CNRS, UMR 5236, 4 Bd Henri IV, CS 69033, F-34965 Montpellier, Cedex 2, France
    • Université Montpellier 2, CPBS, F-34095 Montpellier, France
    • ,
  • Zakia Morichaud

      Affiliations

    • Université Montpellier 1, Centre d’études d’agents Pathogènes et Biotechnologies pour la Santé (CPBS), CNRS, UMR 5236, 4 Bd Henri IV, CS 69033, F-34965 Montpellier, Cedex 2, France
    • Université Montpellier 2, CPBS, F-34095 Montpellier, France
    • ,
  • Konstantin Brodolin

      Affiliations

    • Université Montpellier 1, Centre d’études d’agents Pathogènes et Biotechnologies pour la Santé (CPBS), CNRS, UMR 5236, 4 Bd Henri IV, CS 69033, F-34965 Montpellier, Cedex 2, France
    • Université Montpellier 2, CPBS, F-34095 Montpellier, France
    • ,
  • Jean-Paul Leonetti

      Affiliations

    • Université Montpellier 1, Centre d’études d’agents Pathogènes et Biotechnologies pour la Santé (CPBS), CNRS, UMR 5236, 4 Bd Henri IV, CS 69033, F-34965 Montpellier, Cedex 2, France
    • Université Montpellier 2, CPBS, F-34095 Montpellier, France

References 

  1. Sensi P, Greco AM, Ballotta R. Rifomycin I. Isolation and properties of rifomycin B and rifomycin complex. Antibiot Annu. 1959;7:262–270
  2. Sensi P, Ballotta R, Greco M. Rifomycin V, Rifomycin O. A new antibiotic of the rifomycin family. Farmaco Sci. 1960;15:228–234
  3. Gardner MJ, Williamson DH, Wilson RJM. A circular DNA in malaria parasites encodes an RNA polymerase like that of prokaryotes and chloroplasts. Mol Biochem Parasitol. 1991;44:115–123
  4. Pukrittayakamee S, Viravan C, Charoenlarp P, Yeamput C, Wilson RJ, White NJ. Antimalarial effects of rifampin in Plasmodium vivax malaria. Antimicrob Agents Chemother. 1994;38:511–514
  5. Yim G, Huimi HH, Davies J. Antibiotics as signalling molecules. Philos Trans R Soc Lond B Biol Sci. 2007;362:1195–1200
  6. Villain-Guillot P, Bastide L, Gualtieri M, Leonetti J-P. Progress in targeting bacterial transcription. Drug Discov Today. 2007;12:200–208
  7. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001;104:901–912
  8. Floss HG, Yu TW. Rifamycin—mode of action, resistance, and biosynthesis. Chem Rev. 2005;105:621–632
  9. Jin DJ, Gross CA. RpoB8, a rifampicin-resistant termination-proficient RNA polymerase, has an increased Km for purine nucleotides during transcription elongation. J Biol Chem. 1991;266:14478–14485
  10. Severinov K, Soushko M, Goldfarb A, Nikiforov V. Rifampicin region revisited. New rifampicin-resistant and streptolydigin-resistant mutants in the β subunit of Escherichia coli RNA polymerase. J Biol Chem. 1993;268:14820–14825
  11. Severinov K, Soushko M, Goldfarb A, Nikiforov V. RifR mutations in the beginning of the Escherichia coli rpoB gene. Mol Gen Genet. 1994;244:120–126
  12. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341:647–650
  13. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998;79:3–29
  14. Heep M, Odenbreit S, Beck D, Decker J, Prohaska E, Rieger U, et al. Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins. Antimicrob Agents Chemother. 2000;44:1713–1715
  15. Heep M, Rieger U, Beck D, Lehn N. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2000;44:1075–1077
  16. Heep M, Brandstatter B, Rieger U, Lehn N, Richter E, Rusch-Gerdes S, et al. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J Clin Microbiol. 2001;39:107–110
  17. Perkins AE, Nicholson WL. Uncovering new metabolic capabilities of Bacillus subtilis using phenotype profiling of rifampin-resistant rpoB mutants. J Bacteriol. 2008;190:807–814
  18. Maguire BA, Wild DG. Identification of a mutation conferring antibiotic dependence in Escherichia coli. In: 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25–28 October 2008, Washington, DC. Washington, DC: ASM Press; 2008;p. 124
  19. Sonenshein AL, Cami B, Brevet J, Cote R. Isolation and characterization of rifampin-resistant and streptolydigin-resistant mutants of Bacillus subtilis with altered sporulation properties. J Bacteriol. 1974;120:253–265
  20. Kawamura N, Kurokawa K, Ito T, Hamamoto H, Koyama H, Kaito C, et al. Participation of Rho-dependent transcription termination in oxidative stress sensitivity caused by an rpoB mutation. Genes Cells. 2005;10:477–487
  21. Hu H, Zhang Q, Ochi K. Activation of antibiotic biosynthesis by specified mutations in the rpoB gene (encoding the RNA polymerase β subunit) of Streptomyces lividans. J Bacteriol. 2002;184:3984–3991
  22. Bergval IL, Klatser PR, Schuitema ARJ, Oskam L, Anthony RM. Specific mutations in the Mycobacterium tuberculosis rpoB gene are associated with increased dnaE2 expression. FEMS Microbiol Lett. 2007;275:338–343
  23. Jin DJ, Walter WA, Gross CA. Characterization of the termination phenotypes of rifampicin-resistant mutants. J Mol Biol. 1988;202:245–253
  24. Adone R, Ciuchini F, Marianelli C, Tarantino M, Pistoia C, Marcon G, et al. Protective properties of rifampin-resistant rough mutants of Brucella melitensis. Infect Immun. 2005;73:4198–4204
  25. Björkman J, Hughes D, Andersson DI. Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA. 1998;95:3949–3953
  26. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJM. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312:1944–1946
  27. Enne VI, Delsol AA, Roe JM, Bennett PM. Rifampicin resistance and its fitness cost in Enterococcus faecium. J Antimicrob Chemother. 2004;53:203–207
  28. Kageyama A, Yazawa K, Ishikawa J, Hotta K, Nishimura K, Mikami Y. Nocardial infections in Japan from 1992 to 2001, including the first report of infection by Nocardia transvalensis. Eur J Epidemiol. 2004;19:383–389
  29. Schaal KP, Lee H-J. Actinomycete infections in humans—a review. Gene. 1992;115:201–211
  30. Wauters G, Avesani V, Charlier J, Janssens M, Vaneechoutte M, Delmee M. Distribution of Nocardia species in clinical samples and their routine rapid identification in the laboratory. J Clin Microbiol. 2005;43:2624–2628
  31. Ishikawa J, Yamashita A, Mikami Y, Hoshino Y, Kurita H, Hotta K, et al. The complete genomic sequence of Nocardia farcinica IFM 10152. Proc Natl Acad Sci USA. 2004;101:14925–14930
  32. Ishikawa J, Chiba K, Kurita H, Satoh H. Contribution of rpoB2 RNA polymerase β subunit gene to rifampin resistance in Nocardia species. Antimicrob Agents Chemother. 2006;50:1342–1346
  33. Vigliotta G, Tredici SM, Damiano F, Montinaro MR, Pulimeno R, di Summa R, et al. Natural merodiploidy involving duplicated rpoB alleles affects secondary metabolism in a producer actinomycete. Mol Microbiol. 2005;55:396–412
  34. Inaoka T, Takahashi K, Yada H, Yoshida M, Ochi K. RNA polymerase mutation activates the production of a dormant antibiotic 3,3′-neotrehalosadiamine via an autoinduction mechanism in Bacillus subtilis. J Biol Chem. 2004;279:3885–3892
  35. Newell KV, Thomas DP, Brrekasis D, Paget MS. The RNA polymerase-binding protein RbpA confers basal levels of rifampicin resistance on Streptomyces coelicolor. Mol Microbiol. 2006;60:687–696
  36. Hu Y, Mangan JA, Dhillon J, Sole KM, Mitchison DA, Butcher PD, et al. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol. 2000;182:6358–6365
  37. Pomerantz RT, O’Donnell M. The replisome uses mRNA as a primer after colliding with RNA polymerase. Nature. 2008;456:762–766
  38. Flåtten I, Morigen K, Morigen S. DnaA protein interacts with RNA polymerase and partially protects it from the effect of rifampicin. Mol Microbiol. 2009;71:1018–1030
  39. Wegrzyn A, Szalewska-Palasz A, Blaszczak A, Liberek K, Wegrzyn G. Differential inhibition of transcription from sigma70- and sigma32-dependent promoters by rifampicin. FEBS Lett. 1998;440:172–174
  40. Vassylyev DG, Vassylyeva MN, Perederina A, Tahirov TH, Artsimovitch I. Structural basis for transcription elongation by bacterial RNA polymerase. Nature. 2007;448:157–162
  41. Imai T, Watanabe K, Mikami Y, Yazawa K, Ando A, Nagata Y, et al. Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis. Microb Drug Resist. 1999;5:259–264
  42. Combrink KD, Denton DA, Harran S, Ma Z, Chapo K, Yan D, et al. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases. Bioorg Med Chem Lett. 2007;17:522–526
  43. Dabbs E, Yazawa K, Tanaka Y, Mikami Y, Miyaji M, Andersen S, et al. Rifampicin inactivation by Bacillus species. J Antibiot (Tokyo). 1995;48:815–819
  44. Tanaka Y, Yazawa K, Dabbs E, Nishikawa K, Komaki H, Mikami Y, et al. Different rifampicin inactivation mechanisms in Nocardia and related taxa. Microbiol Immunol. 1996;40:1–4
  45. Hui J, Gordon N, Kajioka R. Permeability barrier to rifampin in mycobacteria. Antimicrob Agents Chemother. 1977;11:773–779
  46. Siddiqi N, Das R, Pathak N, Banerjee S, Ahmed N, Katoch VM, et al. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a tap-like efflux pump. Infection. 2004;32:109–111
  47. Fernandes P, Ferreira BS, Cabral JMS. Solvent tolerance in bacteria: role of efflux pumps and cross-resistance with antibiotics. Int J Antimicrob Agents. 2003;22:211–216
  48. Maness M, Sparling P. Multiple antibiotic resistance due to a single mutation in Neisseria gonorrhoeae. J Infect Dis. 1973;128:321–330
  49. Hagman K, Pan W, Spratt B, Balthazar J, Judd R, Shafer W. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology. 1995;141:611–622

PII: S0924-8579(10)00017-8

doi: 10.1016/j.ijantimicag.2009.12.017

International Journal of Antimicrobial Agents
Volume 35, Issue 6 , Pages 519-523 , June 2010

Article Tools

* Image Usage & Resolution